OBJECTIVE: We sought to compare mortality reduction associated with secondary prevention in patients with and without diabetes after acute coronary syndrome (ACS). RESEARCH DESIGN AND METHODS: We conducted a cohort study involving 2,499 patients with ACS recruited from 11 U.K. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients with and without diabetes. RESULTS: Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50-1.08); nondiabetic patients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use. CONCLUSIONS: Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.
OBJECTIVE: We sought to compare mortality reduction associated with secondary prevention in patients with and without diabetes after acute coronary syndrome (ACS). RESEARCH DESIGN AND METHODS: We conducted a cohort study involving 2,499 patients with ACS recruited from 11 U.K. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients with and without diabetes. RESULTS:Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50-1.08); nondiabeticpatients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use. CONCLUSIONS:Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.
Authors: Päivi Ruokoniemi; Maarit J Korhonen; Arja Helin-Salmivaara; Piia Lavikainen; Antti Jula; Seppo Y T Junnila; Raimo Kettunen; Risto Huupponen Journal: Br J Clin Pharmacol Date: 2011-05 Impact factor: 4.335
Authors: Matthew B Kahn; Nadira Y Yuldasheva; Richard M Cubbon; Jessica Smith; Sheikh T Rashid; Hema Viswambharan; Helen Imrie; Afroze Abbas; Adil Rajwani; Amir Aziz; Vivek Baliga; Piruthivi Sukumar; Matthew Gage; Mark T Kearney; Stephen B Wheatcroft Journal: Diabetes Date: 2011-02-11 Impact factor: 9.461